Abstract：
Insect cell expression has been successfully used for the production of viral antigens as part of commercial vaccine development. As expression host, insect cells offer advantage over bacterial system by presenting the ability of performing post-translational modifications (PTMs) such as glycosylation and phosphorylation thus preserving the native functionality of the proteins especially for viral antigens. Insect cells have limitation in exactly mimicking some proteins which require complex glycosylation pattern. The recent advancement in insect cell engineering strategies could overcome this limitation to some extent. Moreover, cost efficiency, timelines, safety, and process adoptability make insect cells a preferred platform for production of subunit antigens for human and animal vaccines. In this chapter, we describe the method for producing the SARS-CoV2 spike ectodomain subunit antigen for human vaccine development and the virus like particle (VLP), based on capsid protein of porcine circovirus virus 2 (PCV2d) antigen for animal vaccine development using two different insect cell lines, SF9 & Hi5, respectively. This methodology demonstrates the flexibility and broad applicability of insect cell as expression host.
摘要：
作为商业疫苗开发的一部分，昆虫细胞表达已成功用于生产病毒抗原。作为表达式宿主,昆虫细胞通过呈现进行翻译后修饰(PTM)(例如糖基化和磷酸化)的能力而提供优于细菌系统的优势,从而保留蛋白质的天然功能性,特别是对于病毒抗原。昆虫细胞在精确模拟一些需要复杂糖基化模式的蛋白质方面具有局限性。昆虫细胞工程策略的最新进展可以在一定程度上克服这一限制。此外，成本效率，时间线,安全,和过程可采用性使昆虫细胞成为生产人类和动物疫苗亚基抗原的首选平台。在这一章中,我们描述了用于人类疫苗开发的SARS-CoV2刺突胞外域亚基抗原和病毒样颗粒（VLP）的产生方法，基于猪圆环病毒2（PCV2d）抗原的衣壳蛋白，用于使用两种不同的昆虫细胞系开发动物疫苗，分别为SF9和Hi5。该方法证明了昆虫细胞作为表达宿主的灵活性和广泛适用性。
